Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720499 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT00720499 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 141 participants.
The verdict
NCT00720499, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).
Interventions
- DEVICE Respimat® Inhaler
- DRUG BI 1744 CL plus tiotropium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720499
The ClinicalTrials.gov registry entry for NCT00720499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Respimat® Inhaler is the first listed.
NCT00720499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720499 about?
NCT00720499 is a clinical study titled "Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)". The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00720499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2008-07.
What interventions are being tested in trial NCT00720499?
The interventions under investigation include: Respimat® Inhaler (DEVICE), BI 1744 CL plus tiotropium bromide (DRUG).
Who is sponsoring clinical trial NCT00720499?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.